The exploratory analyses indicating similar risk of intracranial hemorrhage with FXI/FXIa inhibitors and DOACs, if borne out in the ongoing Phase 3 studies, would imply that use of FXIa inhibitors would not be preferred over DOACs in those with prior stroke, cerebral small vessel disease or amyloid angiopathy. The gene discussed is F11; the disease is intracranial hemorrhage.